Faeth Therapeutics (FTH)
NASDAQ:FTH
Want to see FTH full AI Analyst Report?
FTH Stock Chart & Stats
$11.42
-$0.03(-5.03%)
At close: 4:00 PM EST
$11.42
-$0.03(-5.03%)
Day’s Range― - ―
52-Week Range$6.18 - $36.76
Previous CloseN/A
VolumeN/A
Average Volume (3M)38.93K
Market Cap
$19.50M
Enterprise Value-$128.96M
Total Cash (Recent Filing)$202.79M
Total Debt (Recent Filing)$1.04M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Aug 11, 2026EPS Estimate
-5.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-147.90
Shares Outstanding1,341,941
10 Day Avg. Volume109,584
30 Day Avg. Volume38,927
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.72
Price to Sales (P/S)0.00
P/FCF Ratio-0.66
Enterprise Value/Market Cap-6.61
Enterprise Value/Revenue26.58
Enterprise Value/Gross Profit0.97
Enterprise Value/Ebitda0.70
Forecast
1Y Price Target
$53.33Price Target Upside367.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-118.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageLow recorded debt reduces interest burden and preserves capital flexibility. Over the next 2–6 months this strengthens the firm's ability to raise non-destrictive financing or pursue partnerships without immediate solvency pressure, supporting runway management during clinical development.
Clinical-stage Immunotherapy FocusA focused R&D platform in antibody- and cytokine-based immunotherapies targets solid tumors, creating a durable competitive niche. Platform specialization supports scientific differentiation, potential high-value assets, and partnership appeal over the medium term if clinical progress continues.
Narrowing Operating Losses (2022–2025)A multi-year trend of narrowing losses indicates improving cost discipline or more efficient R&D allocation. Sustained narrowing can extend runway and reduce the scale of required financing, enhancing operational sustainability while the company advances clinical programs.
Bears Say
No Meaningful RevenueAbsence of product or recurring revenue forces reliance on external funding and partner deals to support operations. Over months this elevates execution risk, ties program progress to financing events, and prevents internal cash generation needed to self-fund trials or scale.
Negative Stockholders' Equity (TTM)Negative equity reflects cumulative losses that can constrain borrowing, reduce financial flexibility, and increase the likelihood of dilutive capital raises. This structural balance-sheet weakness can limit strategic options and raise cost of capital over the medium term.
Persistent Negative Cash FlowConsistent negative operating and free cash flow indicates ongoing funding needs to sustain R&D. Over 2–6 months this necessitates capital markets or partnership financing, raising execution and dilution risk and potentially forcing prioritization or delay of programs.
Faeth Therapeutics News
FTH FAQ
What was Faeth Therapeutics’s price range in the past 12 months?
Faeth Therapeutics lowest stock price was $6.18 and its highest was $36.76 in the past 12 months.
What is Faeth Therapeutics’s market cap?
Faeth Therapeutics’s market cap is $19.50M.
When is Faeth Therapeutics’s upcoming earnings report date?
Faeth Therapeutics’s upcoming earnings report date is Aug 11, 2026 which is in 53 days.
How were Faeth Therapeutics’s earnings last quarter?
Faeth Therapeutics released its earnings results on May 15, 2026. The company reported -$131.45 earnings per share for the quarter, missing the consensus estimate of -$0.62 by -$130.83.
Is Faeth Therapeutics overvalued?
According to Wall Street analysts Faeth Therapeutics’s price is currently Undervalued.
Does Faeth Therapeutics pay dividends?
Faeth Therapeutics does not currently pay dividends.
What is Faeth Therapeutics’s EPS estimate?
Faeth Therapeutics’s EPS estimate is -5.05.
How many shares outstanding does Faeth Therapeutics have?
Faeth Therapeutics has 1,341,941 shares outstanding.
What happened to Faeth Therapeutics’s price movement after its last earnings report?
Faeth Therapeutics reported an EPS of -$131.45 in its last earnings report, missing expectations of -$0.62. Following the earnings report the stock price went up 3.078%.
Which hedge fund is a major shareholder of Faeth Therapeutics?
Currently, no hedge funds are holding shares in FTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Faeth Therapeutics
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
FTH Stock 12 Month Forecast
Average Price Target
$53.33
▲(367.02% Upside)
Technical Analysis
Cellectar Biosciences
―
Cocrystal Pharma
―
BioRestorative Therapies
―
―
Bolt Biotherapeutics
―
Ownership Overview
53.09% Insiders
1.40% Mutual Funds
2.69% Other Institutional Investors
42.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---